Dissemin is shutting down on January 1st, 2025

Published in

Cambridge University Press, British Journal of Psychiatry, 5(199), p. 380-385, 2011

DOI: 10.1192/bjp.bp.111.091421

Links

Tools

Export citation

Search in Google Scholar

Cannabis, COMT and psychotic experiences

Journal article published in 2011 by Stanley Zammit ORCID, Michael J. Owen, Jonathan Evans ORCID, Jon Heron, Glyn Lewis ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

BackgroundA putative interaction between cannabis and variation at rs4680 within the catechol-methyl-transferase (COMT) gene on psychosis has been reported, but not adequately replicated.AimsTo examine whether the relative risk of developing psychosis following use of cannabis is dependent upon variation within COMT.MethodA longitudinal study of 2630 individuals from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort who completed questionnaire-based assessments for cannabis use at age 14 and incident psychotic experiences at age 16. Six SNPs within COMT were genotyped.ResultsThere was no evidence of an interaction under multiplicative models between cannabis use and COMT on the risk of developing psychotic experiences in our primary analyses. In sensitivity analyses we observed highly variable evidence of interaction, whereby psychotomimetic effects of cannabis were greater in methionine homozygotes under some scenarios, but in valine homozygotes under others.ConclusionsCannabis increases risk of psychosis irrespective of underlying COMT genotypes. These findings argue against the widely held belief that the relative risk of developing psychosis following use of cannabis is dependent upon variation within COMT. The public health message about the potential increase in risk of psychotic disorders following cannabis use should not be tempered by reports that this harm is subgroup specific in the absence of robust evidence of replication.